Sociedad Americana de Hirudoterapia

Leech-Assisted Flap Salvage — Systematic Review of 277 Cases

Evidence base for the FDA-cleared microsurgical indication

Clinical TrialsWhitaker et al. (2012)MicrosurgeryDOI →

Why this matters for hirudotherapy

Defines the evidence base for the only FDA-cleared indication for medicinal leeches. Demonstrates that infection prophylaxis is the single most important modifiable factor in outcomes, directly informing clinical protocols.

FDA-Cleared Indication

Indicación autorizada por la FDA. Las sanguijuelas medicinales tienen autorización 510(k) de la FDA para el alivio de la congestión venosa después de cirugía reconstructiva.

Last Updated: March 5, 2026Reviewed by: Andrei Dokukin, MD

Alcance y metodología

Whitaker et al. conducted the most comprehensive systematic review of leech-assisted tissue salvage to date, analyzing 277 reported cases across 67 publications spanning 1966–2009. The review covered free flap reconstructions, pedicled flaps, replantations, and composite tissue transfers where leeches were used to manage venous congestion — the FDA-cleared indication.[R1]

Hallazgos clave

60–83%

Overall flap salvage rate

88.3%

Salvage without infection

37.4%

Salvage with Aeromonas

La paradoja de la infección

The review’s most significant finding was the dramatic impact of Aeromonas infection on outcomes. Medicinal leeches carry Aeromonas species as obligate gut symbionts — bacteria essential for the leech’s digestion of blood meals. This creates an inherent infection risk during any leech application.

When Aeromonas infection occurred, the flap salvage rate dropped catastrophically — from 88.3% to just 37.4%. This 50-percentage-point reduction established infection prophylaxis as the single most important modifiable factor in leech-assisted flap salvage outcomes.[R1]

Mecanismos de salvamento

The review identified three overlapping mechanisms by which leeches relieve venous congestion:

1. Active extraction

Each leech ingests 5–15 mL of blood during feeding, providing immediate mechanical decompression of the congested tissue.

2. Passive oozing

The anticoagulant-rich bite wound continues to ooze for 4–48 hours post-detachment, removing an additional 50–150 mL per bite site — the primary therapeutic mechanism.

3. Vasodilation

Salivary compounds promote local vasodilation and microcirculatory improvement, enhancing tissue perfusion beyond the immediate bite area.

Implicaciones clínicas

The review established several evidence-based recommendations that have shaped modern clinical practice:

FactorEvidenceRecommendation
Antibiotic prophylaxis88.3% vs 37.4% with/without infectionMandatory fluoroquinolone prophylaxis
TimingEarlier intervention = better outcomesInitiate within 24 hours of congestion
MonitoringBlood loss requires trackingSerial Hgb monitoring; transfusion threshold

El momento como factor pronóstico

A subsequent systematic review by Herlin et al. (2017) extended the Whitaker analysis and identified timing as the dominant prognostic variable: flap salvage was 83.7% when leeches were applied within 24 hours of congestion onset, but dropped to just 38.6% beyond 24 hours — a 45-percentage-point decline. This finding underscores the urgency of early recognition and intervention for venous congestion.

Infection risk is manageable

La infección por Aeromonas es el riesgo principal, pero es prevenible. La profilaxis universal con fluoroquinolonas (típicamente ciprofloxacina) iniciada antes o al momento de la aplicación de sanguijuelas ha reducido las tasas de infección por Aeromonas a casi cero en instituciones con protocolos estandarizados.

References

  • [R1]

    By What Mechanism Do Leeches Help to Salvage Ischaemic Tissues After Reconstructive Surgery? A Systematic Review

    Primary source. Largest systematic review of leech-assisted flap salvage.

  • [R2]

    Leech Therapy in Flap Salvage: Systematic Review and Practical Recommendations

    Journal of Plastic, Reconstructive & Aesthetic Surgery(2017)https://doi.org/10.1016/j.bjps.2016.09.009

    Herlin et al. follow-up review establishing timing as dominant prognostic variable.

  • [R3]

    Medicinal Leech Use in Microsurgery: A Practical Review

    Annals of Plastic Surgery(2012)https://doi.org/10.1097/SAP.0b013e3182183f2a

    Nguyen et al. reviewing institutional protocols and prophylaxis strategies.

Recursos relacionados

Added to ASH library: February 27, 2026 | Site last updated: March 14, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.